Mesoblast (MESO) EBT (2015 - 2023)

Mesoblast has disclosed EBT across 9 years of filings, most recently posting -$22.0 million for Q2 2023.

• EBT for Q2 2023 came in at -$22.0 million, down 2.1% year-over-year; the trailing twelve-month figure through Jun 2023 was -$82.1 million (up 10.36% YoY), and the FY2025 annual result was -$101.8 million, down 15.5% from the prior year.
• EBT came in at -$22.0 million for Q2 2023 at Mesoblast, down from -$18.6 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$7.4 million in Q3 2019 to a low of -$35.9 million in Q2 2020.
• The 5-year median for EBT is -$23.3 million (2019), against an average of -$22.9 million.
• Across the five-year window, EBT soared 63.3% in 2019 and slumped 240.8% in 2020, its largest moves.
• Mesoblast's EBT stood at -$26.9 million in 2019, then climbed by 4.6% to -$25.6 million in 2020, then slipped by 1.59% to -$26.0 million in 2021, then increased by 5.64% to -$24.6 million in 2022, then climbed by 10.58% to -$22.0 million in 2023.
• The last three EBT figures came in at -$22.0 million (Q2 2023), -$18.6 million (Q1 2023), and -$24.6 million (Q4 2022), per Business Quant data.